Feature | |
---|---|
Sex, female/male | 126/16 |
Age, mean ± SD yrs | 55 ± 13 |
SSc duration since diagnosis, mean ± SD yrs | 6.8 ± 9.5 |
Raynaud’s phenomenon duration, mean ± SD yrs | 16 ± 12 |
Subset of dcSSc/lcSSc2, no. | 56/86 |
ANA pattern, n (%) | |
Speckled | 24 (17) |
Speckled and nucleolar | 10 (7) |
Nucleolar | 44 (31) |
Centromere | 64 (45) |
SSc-specific autoantibody, n (%) | |
Anti-topo I | 44 (31) |
ACA | 64 (45) |
None | 34 (24) |
Disease Activity Index19 | 2.2 ± 1.7 |
Disease Severity Index20 | 4.9 ± 2.4 |
Disease features, n (%) | |
Interstitial lung disease | 64 (45) |
Scleroderma renal crisis | 3 (2) |
Myositis | 10 (7) |
Pulmonary arterial hypertension | 48 (34) |
dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; ANA: antinuclear antibodies; anti-topo I: anti-topoisomerase I; ACA: anticentromere antibody.